Van Bockstal MR, Agahozo MC, Koppert LB, van Deurzen CHM. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. Int J Cancer. 2020;146:1189–97.

Article  PubMed  Google Scholar 

Van Bockstal MR, Berlière M, Duhoux FP, Galant C. Interobserver variability in ductal carcinoma in situ of the breast. Am J Clin Pathol. 2020;154:596–609.

Article  PubMed  Google Scholar 

Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. The Lancet. 2016;387:849–56.

Article  CAS  Google Scholar 

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. The Lancet. 2016;387:866–73.

Article  CAS  Google Scholar 

Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev. 2012. https://doi.org/10.1002/14651858.CD007847.pub2.

Article  PubMed  Google Scholar 

Rüschoff J, Lebeau A, Kreipe H, Sinn P, Gerharz CD, Koch W, et al. Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. Mod Pathol. 2017;30:217–26.

Article  PubMed  Google Scholar 

Borgquist S, Zhou W, Jirström K, Amini RM, Sollie T, Sørlie T, et al. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer. 2015;15:1–10.

Article  CAS  Google Scholar 

Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, et al. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Ann Oncol. 2015;26:682–7.

Article  PubMed  CAS  Google Scholar 

Siziopikou KP, Anderson SJ, Cobleigh MA, Julian TB, Arthur DW, Zheng P, et al. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat. 2013;142:415–21.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schiza A, Thurfjell V, Stenmark Tullberg A, Olofsson H, Lindberg A, Holmberg E, et al. Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial. Eur J Cancer. 2022;168:128–37.

Article  PubMed  CAS  Google Scholar 

O’Keefe TJ, Blair SL, Hosseini A, Harismendy O, Wallace AM. HER2-Overexpressing ductal carcinoma in situ associated with increased risk of ipsilateral invasive recurrence, receptor discordance with recurrence. Cancer Prev Res. 2020;13:761–71.

Article  Google Scholar 

Thorat MA, Levey PM, Louise Jones J, Pinder SE, Bundred NJ, Fentiman IS, et al. Prognostic and predictive value of HER2 expression in ductal carcinoma in situ: results from the UK/ANZ DCIS randomized trial. Clin Cancer Res. 2021;27:5317–24.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Van Bockstal M, Libbrecht L, Floris G, Lambein K, Pinder S. Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma? Ann Oncol. 2017;28:2317.

Article  PubMed  Google Scholar 

Weeden CE, Hill W, Lim EL, Grönroos E, Swanton C. Impact of risk factors on early cancer evolution. Cell. 2023;186:1541–63.

Article  PubMed  CAS  Google Scholar 

Strand SH, Rivero-Gutiérrez B, Houlahan KE, Seoane JA, King LM, Risom T, et al. Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: analysis of TBCRC 038 and RAHBT cohorts. Cancer Cell. 2022;40:1521-1536.e7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Risom T, Glass DR, Averbukh I, Liu CC, Baranski A, Kagel A, et al. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell. 2022;185:299-310.e18.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sek P, Zawrocki A, Biernat W, Piekarski JH. HER2 molecular subtype is a dominant subtype of mammary Paget’s cells. An immunohistochemical study. Histopathology. 2010;57:564–71.

Article  PubMed  Google Scholar 

Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, et al. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nat Genet. 2022;54:850–60.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Maxwell AJ, Hilton B, Clements K, Dodwell D, Dulson-Cox J, Kearins O, et al. Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study. Breast. 2022;61:145–55.

Article  PubMed  PubMed Central  Google Scholar 

Maxwell AJ, Clements K, Hilton B, Dodwell DJ, Evans A, Kearins O, et al. Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. Eur J Surg Oncol. 2018;44:429–35.

Article  PubMed  Google Scholar 

Williams KE, Barnes NLP, Cramer A, Johnson R, Cheema K, Morris J, et al. Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol. 2015;26:1019–25.

Article  PubMed  CAS  Google Scholar 

Van Bockstal M, Lambein K, Denys H, Braems G, Nuyts A, Van den Broecke R, et al. Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype. Virchows Arch. 2014;465:275–89.

Article  PubMed  Google Scholar 

Miligy IM, Toss MS, Gorringe KL, Lee AHS, Ellis IO, Green AR, et al. The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. Br J Cancer. 2019;120:1075–82.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yang L, Shen M, Qiu Y, Tang T, Bu H. Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy. Breast. 2022;64:1–6.

Article  PubMed  PubMed Central  Google Scholar 

Akrida I, Mulita F. The clinical significance of HER2 expression in DCIS. Med Oncol. 2023;40:1.

Google Scholar 

Ringberg A, Anagnostaki L, Anderson H, Idvall I, Fernoë M. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer. 2001;37:1514–22.

Article  PubMed  CAS  Google Scholar 

Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer. 2003;39:622–30.

Article  PubMed  CAS  Google Scholar 

Barnes NLP, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res. 2005;11:2163–8.

Article  PubMed  CAS  Google Scholar 

Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, et al. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat. 2009;118:131–7.

Article  PubMed  Google Scholar 

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102:627–37.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Holmes P, Lloyd J, Chervoneva I, Pequinot E, Cornfield DB, Schwartz GF, et al. Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone. Cancer. 2011;117:3650–7.